Clarivate: A 3x-Levered Melting Ice Cube With One Insider Buying the Puddle

# Clarivate: A 3x-Levered Melting Ice Cube With One Insider Buying the Puddle

Clarivate closed around $2.03 this week. A year ago it traded near $4. Two years ago it was a "growth-through-M&A" information services story with a fancy Cortellis AI narrative and analysts modeling upside. Today it's a $4.26 billion debt pile sitting on top of $217.7 million in cash, and the stock chart looks like it's trying to find a floor somewhere in the basement it just dug.

Let's not sugarcoat this one.

The Numbers Don't Lie, Even If the Slide Deck Tries To

Q2 2026, reported July 29, was billed as a beat: $0.19 EPS versus $0.17 expected. Great. Except revenue fell 5.5% year-over-year to $587.3 million, and the company posted a net loss of $268.6 million — a 45.7% net margin, in the wrong direction. EBITDA flipped to negative $14.5 million from a positive $214.2 million just one quarter earlier. That's not a rounding error, that's a company eating a goodwill impairment charge in public, which is management's polite way of admitting that a chunk of its prior acquisitions were worth less than the price tag suggested. Again.

Free cash flow — the one number bulls keep pointing to as proof the lights are still on — is real, but it's shrinking too. $44 million in Q2, down from $115.5 million in Q3 2025. TTM FCF of $464.6 million still services the debt and gets you a P/FCF of 4.16x, which screams "cheap" right up until the deceleration keeps decelerating.

Meanwhile the balance sheet is the whole ballgame here: negative working capital of $221.5 million, a current ratio of 0.85, and debt-to-equity that on a trailing basis blows past 90x book equity. This is a company where the operating business still generates cash, but the capital structure is doing the heavy lifting in terms of what actually happens to shareholders.

The Divestiture Is the Tell

Clarivate held a dedicated investor call on July 6 just to talk about selling its Life Sciences & Healthcare segment. Read between the lines: this isn't strategic simplification for its own sake, it's a company raising cash to delever because the leverage overhang has become the dominant story crowding out everything else — including a Cortellis agentic-AI product story that might otherwise be genuinely interesting. Sell-side has already voted with its price targets: Citi cut to $2.50, Goldman to $2.60, consensus PT drifted from $3.28 down to $2.98 in a matter of weeks. Stifel's still hanging a $5.00 Buy on it, which at this point reads more like faith than forecast.

What's Actually Interesting Here

Two things keep this from being a pure short-and-forget story. First, organic ACV growth ticked up to 1.5% and adjusted margins expanded past 42% — the Value Creation Plan is doing something, even if top-line revenue keeps sliding. Second, and more concretely: director Cornick put roughly $1.7 million of his own money into the stock in early August, a 74% increase in his holdings, right around the $2.00 level. That's not noise — that's someone with a board seat deciding the puddle is worth stepping in. It doesn't erase the leverage math, but it's the kind of signal that's earned some weight against a Snyder sale on the other side of the ledger that was roughly triple the size.

Technically, the stock has actually built a modest base — up 28% off the $1.66 52-week low, reclaiming its 20- and 50-day averages, RSI sitting at a neutral 55. That's a real short-term recovery, not just noise. But zoom out and the 200-day average is still nearly 19% overhead, and this whole bounce is happening inside a downtrend that stretches back to $3.80 in December.

The Verdict

CLVT is not an investment right now. It's a leverage-and-execution bet dressed up in a beaten-down valuation multiple. If the LS&H divestiture closes on decent terms and proceeds actually go toward the debt pile rather than just plugging holes, there's a real de-risking story here, and $2.50–$2.60 isn't a crazy near-term target. If revenue keeps sliding at a 5%+ clip while debt stays put, the 2024 goodwill writedown was a preview, not a finale — and $1.66 stops being a floor and starts being a waypoint.

Small size, tight stop under $1.95, and don't confuse a dead-cat bounce off a 52-week low with a turnaround. The insiders are watching the puddle. So should you — from the edge.